FGEN Overview
Upcoming Projects (FGEN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (FGEN)
-
A Second Look: Examining the IPF treatment landscape with a focus on Pliant's bexotegrast, Fibrogen's pamrevlumab, and United Therapeutics' TYVASO (treprostinil)
Tickers: FGEN, PLRX, UTHR
Executed On: Jun 09, 2023 at 03:10 PM EDT -
Examining the IPF treatment landscape with a focus on Pliant's bexotegrast, Fibrogen's pamrevlumab, and United Therapeutics' TYVASO (treprostinil)
Tickers: FGEN, PLRX, UTHR
Executed On: Jun 01, 2023 at 07:00 AM EDT -
A Second Look: Discussing the Phase 3 LELANTOS data of FibroGen's Pamrevlumab in patients with non-ambulatory DMD
Ticker: FGEN
Executed On: Mar 09, 2023 at 02:30 PM EST -
Discussing the Phase 3 LELANTOS data of FibroGen's Pamrevlumab in patients with non-ambulatory DMD
Ticker: FGEN
Executed On: Jan 19, 2023 at 04:00 PM EST
Expired Projects (FGEN)
-
Discussing FibroGen’s Roxadustat in treating anemia in MDS
Ticker: FGEN
Execute By: Jun 30, 2023 -
A Second View: Exploring the potential of FGEN's Pamrevlumab, GLPG1690 and BG00011 in Idiopathic Pulmonary Fibrosis
Tickers: FGEN, GLPG, GILD, BIIB
Execute By: Sep 27, 2019
Upcoming & Overdue Catalysts (FGEN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (FGEN)
-
FibroGen's (FGEN) Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
Ticker: FGEN
Occurred on: Nov 08, 2019 -
AstraZeneca and Astellas working with FibroGen in studies treating CKD anemia, with NDA expected in 2018
Tickers: FGEN, AZN, ALPMY
Occurred on: Oct 01, 2018 -
FibroGen (FGEN) Presents Data from its PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Ticker: FGEN
Occurred on: May 21, 2018 -
FibroGen (FGEN) aiming to complete submission for roxadustat in India in 2017 Q3
Ticker: FGEN
Occurred on: Nov 08, 2017 -
FibroGen safety portion of roxadustat Phase 3 program in line for completion in second quarter 2017
Ticker: FGEN
Occurred on: Oct 31, 2017 -
FibroGen (FGEN) 2/3 for MDS-associated anemia is in line to begin in third quarter of 2017
Ticker: FGEN
Occurred on: Oct 18, 2017 -
FibroGen (FGEN) set to release data on pamrevlumab and fibrosis (IPF) Phase 2 trial in 2017
Ticker: FGEN
Occurred on: Aug 07, 2017 -
FibroGen (FGEN) FG-3019 expect to launch results of 067 Phase 2 study on Idiopathic Pulmonary Fibrosis in third quarter of 2017
Ticker: FGEN
Occurred on: Aug 07, 2017 -
FibroGen (FGEN) aiming to submit China NDA in 2017 Q3 for roxadustat
Ticker: FGEN
Occurred on: Mar 31, 2017 -
In February 2017, the data safety monitoring board recommended that FibroGen (FGEN) continue its Phase 3 roxadustat (FG-4592) programs
Ticker: FGEN
Occurred on: Feb 28, 2017 -
Data readout from two Phase III studies in dialysis and non-dialysis settings in China expected in Year end 2016
Ticker: FGEN
Occurred on: Jan 30, 2017 -
Phase 2 Data of FG3019 Supports Potential for Treatment of Idiopathic Pulmonary Fibrosis
Ticker: FGEN
Occurred on: Mar 11, 2016 -
FibroGen Publishes Roxadustat Phase 2 Data on Patients with Chronic Kidney Disease
Ticker: FGEN
Occurred on: Feb 16, 2016
Strategic Initiatives (FGEN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
